3.5.3. lower urinary tract symptoms/benign prostatic hyperplasia (bph). trial 60 patients undergoing testosterone therapy six months showed significant differences post-void residual urine prostate volume, storage symptoms measured ipss significantly improved, despite increase prostate-specific antigen (psa) level . larger pre-treatment prostate volume predictive factor improvement luts. similarly, placebo-controlled rct including 120 hypogonadal (total testosterone < 12 nmol/l) men mets listed bph surgery, showed testosterone therapy result difference luts severity compared placebo. conversely, improvement ultrasound markers inflammation expression several pro-inflammatory genes found treatment active arm . long-term study 428 men undergoing testosterone therapy eight years demonstrated significant improvements ipss, changes max flow rate (qmax) residual urine volume, also significant increase prostate volume . similar data registry hypogonadism men (rhyme), including 999 patients follow-up three years, demonstrate significant difference psa levels total ipss men undergoing testosterone therapy, compared untreated patients . similar results reported italian registry (siamo-noi), collecting data 432 hypogonadal men fifteen centres . meta-analyses found significant changes luts patients treated testosterone placebo [131-137]. according recent literature, grounds discourage testosterone therapy hypogonadal patients bph/luts evidence limited benefit androgen administration. concern related patients severe luts (ipss > 19), usually excluded rcts; therefore, limiting long-term safety data testosterone therapy specific setting .